dc.contributor
Institut Català de la Salut
dc.contributor
[Wieduwilt MJ] University of California, San Diego Medical Center, La Jolla, CA, USA. [Stock W, Larson RA] University of Chicago Medicine, Chicago, IL, USA. [Advani A] Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. [Luger S] Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA. [Tallman M] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Barba P] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Wieduwilt, Matthew
dc.contributor.author
stock, wendy
dc.contributor.author
Advani, Anjali
dc.contributor.author
Luger, Selina
dc.contributor.author
Larson, Richard
dc.contributor.author
Tallman, Martin
dc.contributor.author
Barba Suñol, Pere
dc.date.accessioned
2025-10-24T10:42:50Z
dc.date.available
2025-10-24T10:42:50Z
dc.date.issued
2022-06-30T06:33:58Z
dc.date.issued
2022-06-30T06:33:58Z
dc.identifier
Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALG. Leukemia. 2021 Jul;35(7):2076–2085.
dc.identifier
https://hdl.handle.net/11351/7765
dc.identifier
10.1038/s41375-021-01213-5
dc.identifier
000635036100001
dc.identifier.uri
https://hdl.handle.net/11351/7765
dc.description.abstract
Acute lymphocytic leukaemia; Chemotherapy
dc.description.abstract
Leucemia linfocítica aguda; Quimioterapia
dc.description.abstract
Leucèmia limfocítica aguda; Quimioteràpia
dc.description.abstract
Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%, P < 0.001). In multivariate analysis, allogeneic HCT showed inferior OS (HR 2.00, 95% CI 1.5–2.66, P < 0.001), inferior DFS (HR 1.62, 95% CI 1.25–2.12, P < 0.001), and increased NRM (HR 5.41, 95% CI 3.23–9.06, P < 0.001) compared to chemotherapy. A higher 5-year relapse incidence was seen with chemotherapy compared to allogeneic HCT (34% vs. 23%, P = 0.011). Obesity was independently associated with inferior OS (HR 2.17, 95% CI 1.63–2.89, P < 0.001), inferior DFS (HR 1.97, 95% CI 1.51–2.57, P < 0.001), increased relapse (1.84, 95% CI 1.31–2.59, P < 0.001), and increased NRM (HR 2.10, 95% CI 1.37–3.23, P < 0.001). For AYA ALL patients in CR1, post-remission therapy with pediatric-style chemotherapy is superior to MA allogeneic HCT for OS, DFS, and NRM.
dc.format
application/pdf
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Leukemia;35(7)
dc.relation
https://doi.org/10.1038/s41375-021-01213-5
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Leucèmia limfoblàstica - Quimioteràpia
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad
dc.title
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
